Download the slides

---

Related articles :

• ATV/r + 3TC
  • SALT
  • ATLAS-M
• LPV/r + 3TC
  • OLE
• DRV/r + 3TC
  • DUAL

---

Table of contents

Switch to DRV/r + 3TC
DUAL Study: switch to DRV/r + 3TC
Original article : Pulido F, Clin Infect Dis 2017; 65:2112-8
Last update : 22/12/2017

Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK

• Dual therapy with DRV/r plus 3TC was non-inferior regarding maintenance of viral suppression and equally well tolerated as DRV/r plus TDF/FTC (or ABC/3TC)
• Persistent virological suppression was maintained after switching to dual therapy with DRV/r plus 3TC
• These results reinforce the efficacy of dual therapy with a fully active boosted PI and 3TC for maintenance of virological suppression

Design

* Randomisation was stratified by baseline nucleos (t)ides

Objective

• Non inferiority of DRV/r + 3TC at W48: % HIV RNA < 50 c/mL by intention to treat-exposed, snapshot analysis (lower margin of the 2-sided 95% CI for the difference = - 12%, 80% power)

Baseline characteristics and disposition at W48

Efficacy results (HIV RNA < 50 c/mL by ITT-e, snapshot) at W48

Virologic outcome at W48

Virologic failure

• HIV RNA > 50 c/mL in the W48 window
• Discontinuation before W48 due to lack of efficacy

Virologic failure and viral blips

HIV- 1 RNA > 400 c/mL and emergence of resistance

Adverse events, %

Percent mean change in fasting lipids according to NRTI backbone at screen

Mean change in eGFR (Cockroft-Gault), mL/min

Back to Table of Contents